EP Patent

EP1543019A2 — Modified pna molecules

Assigned to Roche Innovation Center Copenhagen AS · Expires 2005-06-22 · 21y expired

What this patent protects

The present invention concerns novel drugs for use in combating various diseases. More particularly the invention concerns peptide nucleic acid (PNA) drugs, which are optionally modified in order to obtain novel PNA molecules with cell-specific delivery.

USPTO Abstract

The present invention concerns novel drugs for use in combating various diseases. More particularly the invention concerns peptide nucleic acid (PNA) drugs, which are optionally modified in order to obtain novel PNA molecules with cell-specific delivery.

Drugs covered by this patent

Patent Metadata

Patent number
EP1543019A2
Jurisdiction
EP
Classification
—
Expires
2005-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Roche Innovation Center Copenhagen AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.